Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy
NCT ID: NCT01056835
Last Updated: 2015-05-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
40 participants
INTERVENTIONAL
2009-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Angiotensin II Blockade for Chronic Allograft Nephropathy
NCT00067990
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
NCT04154670
A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
NCT01763580
Efficacy of Pentoxifylline on Rapidly Progressive Glomerulonephritis
NCT00354198
IL-2 for Multi Drug Resistant Nephrotic Syndrome
NCT02455908
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control
prostaglandin I2 analogue
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prostaglandin I2 analogue
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no history of acute rejection
* stable renal function
Exclusion Criteria
* history of biopsy-proven CNI nephrotoxicity
* history of biopsy-proven or clinical acute rejection
* unstable trough level of CNI or extremely low level of CNI
* bleeding tendency(+)
* pregnancy or pregnant-willing
* anticoagulation(+)
* antiplatelet agent (+)
* significant comorbidity(+): Acute coronary syndrome, pneumonia
20 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jongwon Ha
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jongwon Ha, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Beraprost-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.